PPID

Across TCGA pan-cancer cohorts, PPID mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated PPID data layer compared with 28 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher PPID mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated PPID expression acts as an unfavorable survival marker, although some lineages such as PDAC and LSCC show a favorable association.

PDAC, LSCC, and HNSC are the cancer types where PPID mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Quartile	III,IV	0.917	0.532	.016	8	view →
LSCC	DFS	Median	II,III,IV	1.000	0.839	.006	6	view →
HNSC	OS	Tertile	IV	0.883	0.585	.022	5	view →
GBM	DFS	Median	All	0.665	0.839	.015	2	view →
CCRCC	OS	Median	All	0.776	0.889	.040	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

PPID–PDAC (OS)

Open the PDAC breakdown →